BeStock  
Markets › Compare › GLUE vs RIGL

GLUE vs RIGL

Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.

vsvs
GLUE · Monte Rosa Therapeutics$10.17 ▲ 3.04%
RIGL · Rigel Pharmaceuticals$47.99 ▲ 4.08%

One year, rebased to 100

Each line starts at 100 so growth is directly comparable

77136194253312Oct 9, '25Apr 9, '26Oct 7, '26
  • GLUE +20.2%
  • RIGL +69.0%

Head to head

MetricGLUERIGL
Price$10.17$47.99
Change today▲ 3.04%▲ 4.08%
Market cap$867.64M$896.45M
Return, 3 months-58.5%+9.7%
Return, year to date-35.1%+12.0%
Return, 1 year+31.9%+66.9%
P/E (TTM)-5.82.8
P/B1.82.1
P/E percentile vs own 5y12th73rd
Dividend yield––
Revenue growth (YoY, latest qtr)-61.3%-22.6%
Net profit growth (YoY)-253.0%-71.0%
Gross margin–91.4%
Operating margin-633.0%31.5%
Net margin-560.9%116.3%
Return on equity-42.7%126.9%
Analyst target vs. price+177.0%+35.4%
Analyst buy share100%50%
RSI (14)2555
30-day volatility49.8%34.0%
Max drawdown, 1 year-61.0%-50.1%
Trend readStrong downtrendStrong uptrend
Analyst consensusBuyBuy

Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.

What the numbers say

  • RIGL is the largest of the group by market value.
  • RIGL has returned the most over the past year.
  • GLUE carries the lowest trailing P/E.
  • RIGL is growing revenue fastest.
  • RIGL keeps the most profit per dollar of sales.
  • RIGL has been the calmest stock over the last 30 days.

Go deeper

Scroll to Top